China Glimepiride Market Report, 2013-2022 – Focus on the Third-Generation Sulfonylurea Insulin Secretagogue
- Tuesday, December 4, 2018, 17:15
- Finance
- Add a comment
DUBLIN, Dec. 4, 2018 /PRNewswire/ — The “Investigation Report on China’s Glimepiride Market, 2018-2022” report has been added to ResearchAndMarkets.com’s offering. Glimepiride is a third-generation sulfonylurea insulin secretagogue. Sanofi’s brand-name drug (trade name: Amaryl) have been …
Source: https://www.prnewswire.com:443/news-releases/china-glimepiride-market-report-2013-2022—focus-on-the-third-generation-sulfonylurea-insulin-secretagogue-300760001.html
About the Author
adminasapcorp has written 38959 stories on this site.